China Health Group Inc. (HKG:8225)
0.0800
0.00 (0.00%)
Sep 18, 2026, 4:08 PM HKT
China Health Group Revenue
China Health Group had revenue of 22.95M CNY in the half year ending June 30, 2026, with 25.47% growth. This brings the company's revenue in the last twelve months to 29.90M, up 0.39% year-over-year. In the year 2025, China Health Group had annual revenue of 28.56M with 7.98% growth.
Revenue (ttm)
29.90M CNY
Revenue Growth
+0.39%
P/S Ratio
2.28
Revenue / Employee
905.97K CNY
Employees
33
Market Cap
78.63M HKD
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 28.56M | 2.11M | 7.98% |
| Dec 31, 2024 | 26.45M | 5.03M | 23.47% |
| Dec 31, 2023 | 21.43M | 8.34M | 63.67% |
| Dec 31, 2022 | 13.09M | -70.51M | -84.34% |
| Dec 31, 2021 | 83.60M | 538.00K | 0.65% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| WuXi XDC Cayman | 8.02B |
| Adicon Holdings | 3.06B |
| Kindstar Globalgene Technology | 1.10B |
| Yunkang Group | 624.49M |
| Mega Genomics | 413.73M |
| Biosino Bio-Technology and Science Incorporation | 196.98M |
| Zhong Ji Longevity Science Group | 150.07M |
| King International Investment | 143.23M |